Skip to main content
. 2021 Feb 1;29(8):4763–4772. doi: 10.1007/s00520-021-06018-x

Fig. 2.

Fig. 2

Cumulative incidence of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. MRONJ, medication-related osteonecrosis of the jaw